Chinese Journal of Pharmacovigilance ›› 2024, Vol. 21 ›› Issue (7): 836-840.
DOI: 10.19803/j.1672-8629.20240373
HJELMSTRÖM Peter, BOWRING Geoffrey, YUE Qun-Ying, NORÉN G. Niklas
Received:
2024-05-31
Online:
2024-07-15
Published:
2024-07-31
About author:
Peter Hjelmström, Academic background: MD, PhD and Associate Professor from Karolinska Institute in Stockholm, Sweden. Postdoctoral fellowship at Yale University, New Haven, USA. Employment history: Previous recent positions includes Director/CEO of Uppsala Monitoring Centre (UMC), Uppsala, Sweden (2023-Now); Chief Medical Officer of Camurus AB, Lund, Sweden (2016-2023). Past history of working 17 years in the pharmaceutical industry at different companies.
CLC Number:
HJELMSTRÖM Peter, BOWRING Geoffrey, YUE Qun-Ying, NORÉN G. Niklas. Methods for signal management using the global safety database VigiBase[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 836-840.
[1] LINDQUIST M, EDWARDS IR.The WHO programme for international drug monitoring, its database, and the technical support of the Uppsala Monitoring Centre[J]. J Rheumatol, 2001, 28: 1180-1187. [2] VENULET J, BORDA MH.WHO’s International drug monitoring - the formative years, 1968-1975[J]. Drug Saf, 2010, 33: e1-e23. [3] BROWN EG, WOOD L, WOOD S.The medical dictionary for regulatory activities (MedDRA)[J]. Drug Saf, 1999, 20: 109-117. [4] LAGERLUND O, STRESE S, FLADVAD M, et al.WHODrug: a global, validated and updated dictionary for medicinal information[J]. Ther Innov Regul Sci, 2020, 54: 1116-1122. [5] IAN H.Ralph Edwards: Rare Events - The Inside Story of a Worldwide Quest for Safer Medicines[M]. Berlin: Springer, 2003: 302. [6] BERGVALL T, NORÉN GN, LINDQUIST M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues[J]. Drug Saf, 2014, 37: 65-77. [7] PLESSIS L, GÓMEZ A, GARCÍA N, et al. Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia - a restraint to the potentiality for signal detection[J]. Eur J Clin Pharmacol, 2017, 73: 751-758. [8] FERNANDEZ-FERNANDEZ C, LÁZARO-BENGOA E, FERNÁNDEZ-ANTÓN E. et al. Quantity is not enough: completeness of suspected adverse drug reaction reports in Spain- differences between regional pharmacovigilance centres and pharmaceutical industry[J]. Eur J Clin Pharmacol, 2020, 76, 1175-1181. [9] TSUCHIYA M, OBARA T, MIYAZAKI M, et al.The quality assessment of the Japanese Adverse Drug event Report database using vigiGrade[J]. Int J Clin Pharm, 2020, 42: 728-736. [10] WAKAO R, TAAVOLA H, SANDBERG L, et al.Data-driven identification of adverse event reporting patterns for Japan in VigiBase, the WHO Global Database of Individual Case Saf Reports[J]. Drug Saf, 2019, 42: 1487-1498. [11] MATLALA MF, LUBBE MS, STEYN H, et al.The completeness of adverse drug reaction reports in South Africa: An analysis in VigiBase[J]. Afr J Prim Health Care Fam Med, 2023, 15: e1-e9. [12] JOKINEN J, BERTIN D, DONZANTI B, et al.Industry assessment of the contribution of patient support programs, market research programs, and social media to patient safety[J]. Ther Innov Regul Sci, 2019, 53: 736-745. [13] LEE I, JOKINEN JD, CRAWFORD SY, et al.Exploring completeness of adverse event reports as a tool for signal detection in pharmacovigilance[J]. Ther Innov Regul Sci, 2021, 55: 142-151. [14] DITTRICH ATM, SMEETS NJL, DE JONG EFM, et al.Quality of active versus spontaneous reporting of adverse drug reactions in pediatric patients: relevance for pharmacovigilance and knowledge in pediatric medical care[J]. Pharmaceuticals(Basel), 2022, 15: 1148. [15] LEITZEN S, DUBRALL D, TONI I, et al.Adverse drug reactions in children: comparison of reports collected in a pharmacovigilance project versus spontaneously collected ADR Reports[J]. Paediatr Drugs, 2023, 25: 203-215. [16] NORÉN GN, ORRE R, BATEA. Hit-miss model for duplicate detection in the WHO Drug Safety Database[C]. Proceedings of the Eleventh ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, Chicago, Illinois, USA, 2005. [17] NORÉN N, ORRE R, BATE A, et al. Duplicate detection in adverse drug reaction surveillance[J]. Data Min Knowl Discov, 2007, 14: 305-328. [18] TREGUNNO PM, FINK DB, FERNANDEZ-FERNANDEZ C, et al.Performance of probabilistic method to detect duplicate individual case safety reports[J]. Drug Saf, 2014, 37: 249-258. [19] FELLEGI IP, SUNTER AB.A theory for record linkage[J]. J Am Stat Assoc, 1969, 64: 1183-1210. [20] COPAS JB, HILTON FJ.Record linkage: statistical models for matching computer records[J]. J R Stat Soc Ser A Stat Soc, 1990, 153: 287-320. [21] CASTER O, JUHLIN K, WATSON S, et al.Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank[J]. Drug Saf, 2014, 37: 617-628. [22] CASTER O, SANDBERG L, BERGVALL T, et al.vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real-world use[J]. Pharmacoepidemiol Drug Saf, 2017, 26: 1006-1010. [23] STRANDELL J. CASTER O, HOPSTADIUS J, et al.The development and evaluation of triage algorithms for early discovery of adverse drug interactions[J]. Drug Saf, 2013, 36: 371-388. [24] STAR K, SANDBERG L, BERGVAL T, et al.Paediatric safety signals identified in VigiBase: Methods and results from Uppsala Monitoring Centre[J]. Pharmacoepidemiol Drug Saf, 2019, 28: 680-689. [25] WATSON S, CHANDLER RE, TAAVOLA H, et al.Safety concerns reported by patients identified in a collaborative signal detection workshop using VigiBase: results and reflections from lareb and Uppsala Monitoring Centre[J]. Drug Saf, 2018, 41: 203-212. [26] JUHLIN K, STAR K, NORÉN GN. A method for data-driven exploration to pinpoint key features in medical data and facilitate expert review[J]. Pharmacoepidemiol Drug Saf, 2017, 26: 1256-1265. [27] NORÉN GN, HOPSTADIUS J, BATE A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery[J]. Stat Methods Med Res, 2013, 22: 57-69. [28] BERHE DF, JUHLIN K, STAR K, et al.Adverse drug reaction reports for cardiometabolic drugs from sub-Saharan Africa: a study in VigiBase[J]. Trop Med Int Health, 2015, 20(6): 797-806. [29] WAKAO R, TAAVOLA H, SANDBERG L, et al.Data-driven identification of adverse event reporting patterns for Japan in Vigibase, the WHO Global Database of individual case safety reports[J]. Drug Saf, 2019, 42: 1487-1498. [30] EKHART C, VAN HUNSEL F, VAN PUIJENBROEK E, et al.Post-marketing safety profile of vortioxetine using a cluster analysis and a disproportionality analysis of global adverse event reports[J]. Drug Saf, 2022, 45: 145-153. [31] NORÉN GN, MELDAU EL, CHANDLER RE. Consensus clustering for case series identification and adverse event profiles in pharmacovigilance[J]. Artif Intell Med, 2021, 122: 102199. [32] DEMPSTER AP, LAIRD NM, RUBIN DB.Maximum likelihood from incomplete data via the EM algorithm[J]. J R Stat Soc Series B Stat Methodol, 1977, 39: 1-38. [33] NORÉN GN, MELDAU EL, CHANDLER RE. Consensus clustering for case series identification and adverse event profiles in pharmacovigilance[J]. Artif Intell Med, 2021, 122: 102199. [34] CHANG J, BOYD-GRABER J, BLEI DM, et al.Reading tea leaves: how humans interpret topic models[C]. Advances in neural information processing systems, 2009: 288-296. [35] EKHART C, HUNSEL F, CHANDLER R, et al.Post-marketing saf profile of vortioxetine using a cluster analysis and a disproportionality analysis of global adverse event reports[J]. Drug Saf, 2022, 45: 145-153. [36] CHANDLER RE, JUHLIN K, FRANSSON J, et al.Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in VigiBase[J]. Drug Saf, 2017, 40: 81-90. [37] RUDOLPH A, MITCHELL J, BARRETT J, et al. Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge[J]. Ther Adv Drug Saf, 2022, 13: 2042098 6221118972. [38] GATTEPAILLE LM.Using the WHO database of spontaneous reports to build joint vector representations of drugs and adverse drug reactions, a promising avenue for pharmacovigilance[C]. IEEE International Conference on Healthcare Informatics (ICHI), 2019: 1-6. [39] MIKOLOV T, SUTSKEVER I, CHEN K, et al. Distributed representations of words and phrases and their compositionality[J]. Advances in Neural Information Processing Systems, 2013, 26: 1310.4546. [40] MIKOLOV T, CHEN K, CORRADO G, et al.Efficient estimation of word representations in vector space[J]. Computer Science, 2013: 1301.3781. [41] HAZELL L, SHAKIR SAW.Under-reporting of adverse drug reactions: a systematic review[J]. Drug Saf, 2006, 29: 385-396. [42] BEELER PE, STAMMSCHULTE T, DRESSEL H, et al.Hospitalisations related to adverse drug reactions in Switzerland in 2012-2019: characteristics, in-hospital mortality, and spontaneous reporting rate[J]. Drug Saf, 2023, 46: 753-763. |
[1] | LI Mingying, ZHANG Xiaoxia, SUN Xiaoli, ZHAO Yan, HE Miao, LI Yanling, DUAN Wei, YANG Ou. Effect of Sugammadex on Recovery of Patients after Laparoscopic Total Pelvic Floor Reconstruction [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 896-901. |
[2] | SHEN Chen, ZHOU Xian, LIU Jianping. Database and Evaluation Methods for Chinese Herb-Drug Interactions [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 902-908. |
[3] | KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927. |
[4] | LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932. |
[5] | LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936. |
[6] | YANG Xin, YANG Baochun, YANG Yang, SHAO Huan. One Case of Multiple Endocrine Adverse Effect Caused by Sintilimab [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 947-949. |
[7] | YANG Yifan, YANG Yanwei, ZHANG Di, XIE Yin, ZHANG Yong, CHEN Xulin, GAO Sutao, GENG Xingchao, QU Zhe. Quality Control and Test Methods of Human Induced Pluripotent Stem Cells [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 728-734. |
[8] | REN Yuke, JIANG Hua, LI Lulu, LI Shuangxing, HUO Guitao, YANG Yanwei, ZHANG Di, HUANG Ying, GENG Xingchao, LIN Zhi, QU Zhe. Research Advances in the Pathogenesis of Cytokine Release Syndrome Induced by CAR-T Cell Therapy [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 735-741. |
[9] | WANG Chunting, CHEN Yafei. Considerations for Revision of Safety Information in the Post-Marketing Instructions of Chemical Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 776-779. |
[10] | ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789. |
[11] | LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793. |
[12] | CHEN Yaozhe, ZHAN Yunli, SONG Xingdong, ZHU Manyu, OU Xuemei, LI Chuyun. 48 Cases of Hematological Adverse Reactions Associated with Piperacillin Sodium and Tazobactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 794-798. |
[13] | LEI Jianlin, WANG Na, WANG Wenzheng, WANG Yan. One Case of Phenytoin Intoxication Caused by Compound Phenytoin Sodium Ephedrine Hydrochloride and Theophylline Tablets [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 819-822. |
[14] | ZHONG Xinru, YANG Deying, GUAN Tangming, CHEN Ju, JIANG Dongbo. Research Progress in Adverse Reactions Caused by Obinutuzumab in the Treatment of Follicular Lymphoma [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 831-835. |
[15] | ZHU Lei, ZHANG Xian, WANG Ruiyan, LI Ying. Adverse Reactions Reports about Tislelizumab Injection in 447 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 649-653. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||